RAS

[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)] Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.

[Cell Death & Disease] Researchers investigated whether cetuximab-mediated regulation of p38/Nrf2/HO-1 promoted RSL3-induced ferroptosis and played a pivotal role in overcoming drug resistance in KRAS mutant colorectal cancer.

[Cell Reports] Scientists showed that Myc-driven hepatocellular carcinoma was dramatically aggravated in mice with hepatocyte-specific Ptpn11/Shp2 deletion.

[Blood Cancer Journal] To obtain a comprehensive picture of composite genetic driver events and clonal dynamics in subtypes of pediatric acute lymphoblastic leukemia, scientists analyzed tumor-normal whole genome sequencing and expression data from 361 newly diagnosed patients.

[Scientific Reports] Scientists developed an in vitro model of adipose tissue to study adipocyte-fibroblast crosstalk in a hypoxic environment. The model was used to investigate the effect of hypoxia on adipocyte mechanical properties via ras homolog gene family member A (RhoA)/Rho-associated coiled-coil kinases signaling pathways.

[Gut] FVB/NJ mice were hydrodynamically injected with AKT/Ras and Sleeping Beauty transposon to induce hepatocellular carcinoma. Mini-circle and Sleeping Beauty were used to overexpress microRNA-206 in Kupffer cells of mice.